| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Alicja Wolk | Q29998745 |
| Susanna C. Larsson | Q31229298 | ||
| Kerstin Brismar | Q37376842 | ||
| P2093 | author name string | Orsini N | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults | Q28131763 | ||
| Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis | Q28258638 | ||
| Insulin-like growth factors and their binding proteins: biological actions | Q28301853 | ||
| Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 | Q29614193 | ||
| Cancer statistics, 2005 | Q29617572 | ||
| Infections in patients with diabetes mellitus | Q33796634 | ||
| The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies | Q33912702 | ||
| Insulin, insulin-like growth factors and colon cancer: a review of the evidence | Q34428652 | ||
| The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence | Q34500922 | ||
| Diabetes mellitus and risk of colorectal cancer: a meta-analysis | Q34562613 | ||
| Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis | Q34722287 | ||
| Insulin‐like growth factors and diabetes | Q35203380 | ||
| Diabetes mellitus and breast cancer | Q36026132 | ||
| A case-control study of diabetes mellitus and cancer risk | Q36080130 | ||
| Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria | Q36615499 | ||
| Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study | Q36615940 | ||
| Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden | Q38481227 | ||
| Cancer risk in patients with diabetes mellitus | Q42006932 | ||
| Fasting serum glucose level and cancer risk in Korean men and women | Q43943327 | ||
| Mortality from site-specific malignancies in type 2 diabetic patients from Verona | Q44268211 | ||
| Diabetes mellitus and bladder cancer--an epidemiological relationship? | Q44409514 | ||
| Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study | Q46722336 | ||
| A prospective study of obesity and cancer risk (Sweden). | Q48966816 | ||
| Obesity and cancer risk: a Danish record-linkage study. | Q50558110 | ||
| Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. | Q50561038 | ||
| Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. | Q54528957 | ||
| Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults | Q64133523 | ||
| Insulin-like growth factors and cancer | Q67487325 | ||
| Dietary factors and the incidence of cancer of the urinary bladder | Q68357695 | ||
| Bladder cancer in nonsmokers | Q69994235 | ||
| Diabetes mellitus and cancer risk: a multisite case-control study | Q70112049 | ||
| Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus | Q70312575 | ||
| Urinary tract infection and risk of bladder cancer | Q71316031 | ||
| Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice | Q73838225 | ||
| Increased incidence of diabetes mellitus in the patients with transitional cell carcinoma of urinary bladder | Q73873543 | ||
| Diabetes and endometrial cancer in the Iowa women's health study | Q74009311 | ||
| Cancer mortality among diabetics | Q74407148 | ||
| Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk | Q78835876 | ||
| Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada | Q81473970 | ||
| P433 | issue | 12 | |
| P921 | main subject | bladder cancer | Q504775 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 2819-2823 | |
| P577 | publication date | 2006-10-05 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Diabetes mellitus and risk of bladder cancer: a meta-analysis | |
| P478 | volume | 49 |
| Q37105231 | A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors |
| Q39703234 | Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabete |
| Q37072746 | Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence |
| Q36764977 | Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study |
| Q38972582 | Association between diabetes mellitus and oncological outcomes in bladder cancer patients undergoing radical cystectomy |
| Q36486802 | Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study |
| Q34535741 | Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. |
| Q36801180 | Burden of cancer associated with type 2 diabetes mellitus in Japan, 2010-2030 |
| Q33646525 | CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis |
| Q59685223 | Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies |
| Q36117600 | Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures |
| Q35842470 | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis |
| Q36655912 | Cancers of the urinary tract among American Indians and Alaska Natives in the United States, 1999-2004. |
| Q46215779 | Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance |
| Q98288876 | Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes |
| Q37328209 | Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study |
| Q50728227 | Comorbidities associated with bladder dysfunction. |
| Q38167147 | Complications of diabetes therapy. |
| Q44459340 | Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. |
| Q37193648 | Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. |
| Q37802888 | Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs |
| Q36712191 | Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study |
| Q84805451 | Diabetes and Cancer |
| Q38000088 | Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence |
| Q34069053 | Diabetes and cancer I: risk, survival, and implications for screening |
| Q38097984 | Diabetes and cancer relationships |
| Q37982674 | Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. |
| Q26822753 | Diabetes and cancer: two diseases with obesity as a common risk factor |
| Q36614839 | Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women's Health Study |
| Q43748015 | Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan |
| Q35051024 | Diabetes and risk of bladder cancer: evidence from a case-control study in New England |
| Q36637909 | Diabetes and risk of cancer |
| Q42627812 | Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. |
| Q51716837 | Diabetes and urothelial cancer risk: the Multiethnic Cohort study. |
| Q44015613 | Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan |
| Q38052155 | Diabetes mellitus and cancer risk: review of the epidemiological evidence |
| Q37832965 | Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies |
| Q86316589 | Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies |
| Q34599224 | Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies |
| Q36746724 | Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study |
| Q49372368 | Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. |
| Q36286678 | Diabetes mellitus and the risk of bladder cancer: an Italian case–control study |
| Q37280771 | Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies |
| Q85896441 | Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma |
| Q38232006 | Diabetes mellitus: influences on cancer risk |
| Q38195439 | Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. |
| Q37972673 | Diabetes, cancer, and metformin: connections of metabolism and cell proliferation |
| Q37853559 | Diabetes, gestational diabetes and the risk of cancer in women: epidemiologic evidence and possible biologic mechanisms |
| Q35906970 | Diabetes, insulin and cancer risk |
| Q43057683 | Diabetes, prediabetes and cancer mortality |
| Q35929876 | Different patterns in the prognostic value of age for bladder cancer-specific survival depending on tumor stages |
| Q37593873 | Distinguishing incident and prevalent diabetes in an electronic medical records database |
| Q37924944 | Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types? |
| Q53085995 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. |
| Q34475876 | Effect of diabetes mellitus on outcomes of colorectal cancer |
| Q36047132 | Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study |
| Q43450451 | Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. |
| Q37316380 | Effects of a probiotic soy product and physical exercise on formation of pre-neoplastic lesions in rat colons in a short-term model of carcinogenic |
| Q39703769 | Enhanced Urinary Bladder, Liver and Colon Carcinogenesis in Zucker Diabetic Fatty Rats in a Multiorgan Carcinogenesis Bioassay: Evidence for Mechanisms Involving Activation of PI3K Signaling and Impairment of p53 on Urinary Bladder Carcinogenesis |
| Q41110363 | Epigenetic alterations in patients with type 2 diabetes mellitus |
| Q38030454 | Evolution of insulin development: focus on key parameters |
| Q54649308 | Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. |
| Q34326924 | Glargine safety, diabetes and cancer |
| Q46099484 | Glucose metabolism disorders in cancer patients in a Chinese population |
| Q43091072 | Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. |
| Q37529862 | Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. |
| Q34091905 | Glycemic control and prostate cancer progression: Results from the SEARCH database |
| Q61799673 | High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone |
| Q37496102 | Human insulin does not increase bladder cancer risk |
| Q34253363 | Hypertension, diuretics and antihypertensives in relation to bladder cancer |
| Q58486848 | Impact of Comorbidity on Cancer Screening and Diagnosis |
| Q37153221 | Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus |
| Q43747872 | Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study |
| Q33793812 | Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas |
| Q34355418 | Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. |
| Q98566208 | Increased cancer mortality among Japanese individuals with hyperinsulinemia |
| Q34354362 | Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China |
| Q36410079 | Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients |
| Q44027980 | Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy |
| Q36023488 | Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. |
| Q58393670 | Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials |
| Q55069710 | Japanese Clinical Practice Guideline for Diabetes 2016. |
| Q44676240 | Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). |
| Q35810977 | Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study |
| Q50105959 | Metformin and cancer: An existing drug for cancer prevention and therapy |
| Q43015031 | Metformin and cancer: licence to heal? |
| Q50950977 | Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. |
| Q61811000 | National Trends of Bladder Cancer and Trihalomethanes in Drinking Water: A Review and Multicountry Ecological Study |
| Q51330392 | Nuclear anomalies in exfoliated buccal cells in healthy and diabetic individuals and the impact of a dietary intervention. |
| Q37730336 | Obesity, Diabetes and Cancer: A Mechanistic Perspective |
| Q87394052 | Overview |
| Q37813059 | Physical Activity and Genitourinary Cancer Prevention |
| Q38163451 | Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis. |
| Q38417421 | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis |
| Q36013549 | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study |
| Q37735559 | Plasma levels of glucose and insulin in patients with brain tumors |
| Q36152708 | Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. |
| Q36868299 | Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 Behavioral Risk Factor Surveillance System |
| Q33684090 | Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients |
| Q57076958 | Report of the JDS/JCA Joint Committee on Diabetes and Cancer |
| Q50488148 | Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. |
| Q34628009 | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. |
| Q34353701 | Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies |
| Q35691835 | Risk of bladder cancer in patients with diabetes: a retrospective cohort study |
| Q35587424 | Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study |
| Q34509469 | Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan |
| Q24654974 | Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study |
| Q90442504 | Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review) |
| Q36581133 | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. |
| Q38122640 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? |
| Q36994096 | Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? |
| Q36853961 | Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome |
| Q33585663 | Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiological evidence in Asians and non-Asians |
| Q55155677 | Smoking, depression, and hospital costs of respiratory cancers: Examining race and sex variation. |
| Q38036770 | Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin |
| Q26765998 | The Elastin Receptor Complex: A Unique Matricellular Receptor with High Anti-tumoral Potential |
| Q36919504 | The Role of Insulin and Insulin-like Growth Factors in the Increased Risk of Cancer in Diabetes |
| Q35923260 | The association between metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study in China |
| Q35500732 | The burden of cancer risk in Canada's indigenous population: a comparative study of known risks in a Canadian region |
| Q34510892 | The diabetes-cancer link |
| Q36058422 | The double trouble of metabolic diseases: the diabetes-cancer link |
| Q26782839 | The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research |
| Q35582852 | The impact of nutrition in urogenital cancers |
| Q36499082 | The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer |
| Q36031170 | The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese |
| Q36001145 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q35466765 | Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article |
| Q36247512 | Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis |
| Q80233796 | Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study |
| Q87250339 | Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study |
Search more.